Related Experiment Video

Updated: May 9, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Eluting combination drugs from stents

Rajesh Thipparaboina1, Wahid Khan, Abraham J Domb

  • 1Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500037, India.

International Journal of Pharmaceutics
|July 16, 2013
PubMed

Insights

Advancements in drug-eluting stents (DES) aim to improve cardiovascular disease treatment by reducing restenosis and thrombosis. Future DES may combine anti-restenotic and pro-healing agents for enhanced coronary artery disease therapy.

Area of Science:

  • Cardiovascular medicine
  • Biomaterials science
  • Interventional cardiology

Background:

  • Coronary artery disease (CAD) is a leading cause of death globally, often treated with percutaneous coronary intervention (PCI).
  • Bare metal stents (BMS) reduced restenosis but had high rates of in-stent restenosis (ISR), leading to drug-eluting stents (DES).
  • Current DES face challenges with long-term stent thrombosis, necessitating further innovation.

Purpose of the Study:

  • To explore novel DES strategies for improved CAD treatment.
  • To address limitations of current DES, including restenosis and thrombosis.
  • To investigate advanced therapies like biodegradable, polymer-free, bioresorbable, and combination DES.

Main Methods:

  • Review of current stent technologies and their limitations.
  • Exploration of emerging therapeutic approaches for DES development.
  • Discussion of dual-drug eluting strategies combining anti-restenotic and pro-healing agents.
  • Consideration of polymer therapeutics, nanoscale modifications, and gene therapy for drug delivery.

Main Results:

  • Current DES show promise but require further optimization to mitigate risks like stent thrombosis.
  • Dual-DES with sequential release of anti-restenotic and pro-healing drugs are proposed as an ideal therapeutic approach.
  • Advancements in drug delivery systems are crucial for developing next-generation DES.

Conclusions:

  • Future DES development should focus on biodegradable, polymer-free, bioresorbable, and combination platforms.
  • Optimized drug release profiles, particularly dual-drug strategies, are key to reducing neointimal hyperplasia and promoting endothelial healing.
  • Integrating polymer therapeutics, nanoscale surface modifications, and gene therapy holds significant potential for CAD treatment via stent-based therapies.

Keywords:
Anti-restenotic agentCoronary artery diseaseDual-drug eluting stentsGene deliveryPro-healing agents

More Related Videos

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
Enhanced Elimination of Poison01:26

Enhanced Elimination of Poison

Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...